Pipeline Acceleration Offsets Stelara: Core Portfolio Expands (JNJ Q1 2026 Earnings Call)
Export as clean Markdown. Drag & drop into ChatGPT, Claude, or Gemini.
Johnson & Johnson delivered a solid start to the fiscal year with robust top-line operational growth. Despite facing biosimilar competition for its blockbuster drug Stelara, the healthcare giant capitalized on the rapid commercial launch of its newly approved oral plaque psoriasis therapy Icotyde and sustained momentum in its cardiovascular MedTech portfolio. This performance reinforces management's confidence in its upgraded full-year financial guidance and long-term expansion goals.
Core Strength Offsets Stelara Biosimilar Erosion
Johnson & Johnson delivered worldwide sales of $24.1 billion for the first quarter, representing operational growth of 6.4%. Adjusted diluted earnings per share stood at $2.70. This top-line performance reflects strong underlying demand that successfully overcame biosimilar competition for its immunology treatment Stelara.
Raised Targets Reflect Robust Commercial Execution
Management raised its full-year 2026 operational sales growth guidance to a range of 5.9% to 6.9%, representing a midpoint of $100.2 billion. Chief Financial Officer Joseph Wolk also increased the adjusted operational earnings per share target to a range between $11.30 and $11.50.
To support these growth targets, the enterprise continues to maintain its operational margin expansion goals. Joseph Wolk stated: "We are maintaining our guidance for adjusted pretax operating margin to improve by at least 50 basis points in 2026." The company also reaffirmed its full-year free cash flow expectation of approximately $21 billion.
Innovative Therapies Drive Segment Success
Within the Innovative Medicine segment, worldwide sales reached $15.4 billion, reflecting operational growth of 7.4%. This segment expansion was driven by the leading oncology treatment Darzalex, which generated sales of $4.0 billion.
In the MedTech segment, worldwide sales reached $8.6 billion, representing operational growth of 4.6%. Growth was supported by cardiovascular innovation, including strong adoption of Shockwave coronary and peripheral products. Furthermore, the newly launched bladder cancer therapy Inlexzo contributed sales of slightly above $30 million.
Immunology Scaling Underpins Long-Term Vision
During the Q&A session, executives discussed the company's long-term top-line growth trajectory. Jennifer Taubert highlighted that the core portfolio grew 16.6% in the quarter when excluding the biosimilar impact of Stelara. Furthermore, Jennifer Taubert highlighted the strong early launch trajectory of Icotyde, which has already accumulated 1,500 patient prescriptions from over 1,000 unique customers.